A case of idiopathic central serous chorioretinopathy in a 12-year-old male treated with bevacizumab.
A 12-year-old male presented with a chief complaint of a 1-month-history of decreased visual acuity in his right eye. The patient had no past history of steroid use or other systemic diseases. On fundus examination, which included fluorescent angiography (FAG) and optical coherence tomography (OCT), the patient was diagnosed with idiopathic central chorioretinopathy, whose clinical course was monitored without any specific treatments. At the time of admission, the best-corrected visual acuity was 0.5 in the right eye and 1.0 in the left eye. On fundoscopy, a serous detachment of 1 disc diameter in size was observed in the posterior pole. According to the FAG and the OCT, serous neurosensory detachment was present. After two months of monitoring the clinical course, the best corrected visual acuity in the right eye was 0.8, and there was improvement of neurosensory retinal detachment. However, OCT detected recurrence after five months, and the corrected visual acuity was decreased to 0.6. Bevacizumab was then injected into the vitreous cavity. Complete resolution of the subretinal fluid resulted eight months later, and the corrected visual acuity improved to 1.0.
Department of Ophthalmology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
Yu Cheol
YC
Kim
Si Dong
SD
Kim
Kwang Soo
KS
Kim
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D009887:Ophthalmoscopy; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab